MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progressionRupesh Paudel, Marc Schmidt, Matthias Goebeler et al.|Cell Death and Disease|2025Cited by 4